Michalina Mazurkiewicz

Mrs. Michalina Mazurkiewicz

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
PBPatryk Bodnar
Patryk Bodnar
MMMichalina Mazurkiewicz
Michalina Mazurkiewicz
TCTomasz Chwalba
Tomasz Chwalba
EREwa Romuk
Ewa Romuk
ACAnna Ciszek-Chwalba
Anna Ciszek-Chwalba
CWCelina Wojciechowska
Celina Wojciechowska
Heart failure (HF) is a multifactorial clinical syndrome involving many complex processes. The causes may be related to abnormal heart structure and/or function. Changes in the renin-angiotensin-aldosterone system, the sympathetic nervous system, and the natriuretic peptide system are important in the pathophysiology of HF. Dysregulation or overexpression of these processes leads to changes in cardiac preload and afterload, changes in the vascular system, peripheral vascular dysfunction and remodeling, and endothelial dysfunction. One of the important factors responsible for the development of heart failure at the cellular level is oxidative stress. This condition leads to deleterious cellular effects as increased levels of free radicals gradually disrupt the state of equilibrium, and, as a consequence, the internal antioxidant defense system is damaged. This review focuses on pharmacotherapy for chronic heart failure with regard to oxidation–reduction metabolism, with special attention paid to the latest group of drugs, SGLT2 inhibitors—an integral part of HF treatment. These drugs have been shown to have beneficial effects by protecting the antioxidant system at the cellular level.

1 October 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
MKMaciej Kocjan
Maciej Kocjan
MKMichał Kosowski
Michał Kosowski
MMMichalina Mazurkiewicz
Michalina Mazurkiewicz
PMPiotr Muzyk
Piotr Muzyk
KNKrzysztof Nowakowski
Krzysztof Nowakowski
DKDamian Kawecki
Damian Kawecki
Due to their very wide range of indications, anticoagulants are one of the most commonly used drug groups. Although these drugs are characterized by different mechanisms of action, the most common complication of their use is still bleeding episodes, the frequency of which depends largely on the clinical condition of the patient using such therapy. For this reason, to this day, the best method of preventing bleeding complications remains the assessment of bleeding risk using scales such as HAS-BLED. There are many reports in the literature assessing the occurrence of this type of complication after the use of drugs affecting the coagulation process, as well as many reports comparing individual groups of drugs with different mechanisms of action. However, there are still no clear guidelines that would indicate which group of anticoagulants should be preferred in particular groups of patients. The aim of our article is to summarize the data collected so far regarding the safety of using specific groups of anticoagulants and the frequency of bleeding complications after their use.

30 April 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
MMMichalina Mazurkiewicz
Michalina Mazurkiewicz
PBPatryk Bodnar
Patryk Bodnar
Dominika BlachutDominika Blachut
Dominika Blachut
TCTomasz Chwalba
Tomasz Chwalba
WWWiktor Wagner
Wiktor Wagner
CWCelina Wojciechowska
Celina Wojciechowska
Sodium-glucose co-transporter-2 (SGLT-2) inhibitors have become integral in treating both diabetes mellitus and heart failure, independent of left ventricular ejection fraction. Their pleiotropic effect influences multiple mechanisms, enhancing the function of various systems within the body. They exhibit nephroprotective and cardioprotective effects by improving cell metabolism, endothelial function, and slowing the fibrosis of the cardiac muscle, and they also have a beneficial impact on other organs. At the cellular level, they protect against the harmful effects of free radicals both by lowering glucose levels and by supporting the function of the antioxidant system. Moreover, SGLT-2 inhibitors can modify the metabolism of adipocytes by affecting the production of cytokines such as adiponectin—which increases insulin sensitivity, leading to weight loss and improved glycemic control.

5 February 2025 in Applied Sciences
Verified
Journal Article
Open access
PDF file
Dominika BlachutDominika Blachut
Dominika Blachut
MMMichalina Mazurkiewicz
Michalina Mazurkiewicz
MSMarcin Krzysztof Schulz
Marcin Krzysztof Schulz
JCJulia Cieśla
Julia Cieśla
BPBrygida Przywara-Chowaniec
Brygida Przywara-Chowaniec
Andrzej Robert TomasikAndrzej Robert Tomasik
Andrzej Robert Tomasik
Systemic lupus erythematosus (SLE) is a disease that significantly increases cardiovascular risk. Although cardiovascular diseases are one of the leading causes of death in SLE patients, the correlation between SLE and heart failure (HF) remains unexplored. Myocardial dysfunction in SLE patients is frequently asymptomatic or nonspecific, which makes it difficult to identify HF using standard diagnostic techniques. In addition, there are serious difficulties in its early diagnosis. In this review, we summarize the latest reports on the epidemiology of heart failure in SLE patients. Current evidence on the impact of SLE treatment on the development of HF, as well as potential risk factors that increase the risk of HF, is presented. Potential methods of treatment and early detection of HF with special attention to potential biomarkers are also provided. Further research is needed to better understand the mechanisms of the correlation between HF and SLE and to develop effective treatment strategies.

Verified
Journal Article
Open access
PDF file
MKMichał Kosowski
Michał Kosowski
MKMaciej Kocjan
Maciej Kocjan
MMMichalina Mazurkiewicz
Michalina Mazurkiewicz
MGMarta Gamrot-Wrzoł
Marta Gamrot-Wrzoł
SRSabina Ryl
Sabina Ryl
BMBeata Morawiec
Beata Morawiec
Bleeding complications are a significant concern in the management of acute coronary syndromes (ACS). The evidence from clinical trials demonstrates the need for balancing efficacy in reducing ischemic events with safety concerns, as bleeding events adversely affect prognosis and mortality. Pharmacological agents like aspirin, P2Y12 inhibitors (e.g., prasugrel, ticagrelor), glycoprotein IIb/IIIa inhibitors, and heparins are fundamental to ACS treatment but carry varying bleeding risks depending on individual patient profile. Recent advancements in risk stratification tools have enabled tailored approaches to dual antiplatelet therapy (DAPT), optimizing its duration based on bleeding and thrombotic risks. Further Emerging therapies, including shortened DAPT protocols and P2Y12 inhibitor monotherapy, have shown promise in minimizing bleeding while maintaining clinical efficacy. The findings underscore the importance of personalized antithrombotic regimens in ACS management, emphasizing precise risk assessment to enhance outcomes and mitigate adverse events. This review examines the mechanisms, risk factors, and strategies to mitigate bleeding associated with anticoagulant and antiplatelet therapies in ACS.

14 February 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
KBKarolina Barańska-Pawełczak
Karolina Barańska-Pawełczak
WJWojciech Jacheć
Wojciech Jacheć
Andrzej Robert TomasikAndrzej Robert Tomasik
Andrzej Robert Tomasik
BZBettina Ziaja
Bettina Ziaja
MMMichalina Mazurkiewicz
Michalina Mazurkiewicz
CWCelina Wojciechowska
Celina Wojciechowska
Background/Objectives: Cardiac resynchronization therapy (CRT) is one of the interventional methods of heart failure (HF) treatment, with the criteria for CRT device implantation based on the value of the left ventricular ejection fraction, New York Heart Association functional class, QRS complex duration, and electrocardiographic morphology. Pulmonary hypertension is an important factor influencing the prognosis of patients with HF, but its influence on CRT is not fully understood. Aim: The main aim of the study was to determine the prognostic value of baseline right heart catheterization-derived parameters on the response to CRT. Methods: It was a single-centre study with retrospective analysis of data of 39 non-ischemic HF patients. Clinical, biochemical, echocardiographic, electrocardiographic, and hemodynamic data were obtained before the CRT device implantation, and after 6 months of follow-up, non-invasive re-assessment was performed. Various criteria for the response to CRT were assessed along with the correlation between the baseline parameters. Results: After follow-up, a significant difference was found in the reduction in symptoms associated with HF, an increase achieved in the six-minute walk test distance, and a reduction in N-terminal pro-brain natriuretic peptide concentration as well as improvement of LV function assessed in echocardiographic examination. Among all parameters assessed, the baseline higher value of the transpulmonary gradient and pulmonary vascular resistance most often had a significant negative impact on meeting the criteria of response to CRT. Conclusions: The results of the analyses show that the initial assessment of pulmonary hemodynamics may be crucial in predicting the response to CRT in patients with non-ischemic cardiomyopathy.